Anuncio
Anuncio
KLRS
Kalaris Therapeutics, Inc. Common Stock
9.82
USDPatrocinado
+1.56
+18.95%
09 ene, 15:58 UTC -5
Cerrado
Post-mercado
9.99
+0.17
+1.68%
Informes de beneficios de KLRS
Ratio de Sorpresa Positivo
KLRS superó 10 de las últimas 19 estimaciones.
53%
Próximo informe
Fecha del próximo informe
05 mar 2026
Estimate for Q4 25 (Revenue/ EPS)
--
/-$0.54
Cambio implícito desde Q3 25 (Revenue/ EPS)
--
/-15.63%
Cambio implícito desde Q4 24 (Revenue/ EPS)
--
/--
Kalaris Therapeutics, Inc. Common Stock earnings per share and revenue
On 12 nov 2025, KLRS reported earnings of -0.64 USD per share (EPS) for Q3 25, beating the estimate of -0.66 USD, resulting in a 3.89% surprise. Revenue reached --, compared to an expected --, with a 0.00% difference. The market reacted with a -2.17% price change (close before vs. close after earnings).
Looking ahead to Q4 25, 8 analistas forecast an EPS of -0.54 USD, with revenue projected to reach -- USD, implying an reducir of -15.63% EPS, and aumentar of 0.00% in Revenue from the last quarter.
Preguntas frecuentes
What were Kalaris Therapeutics, Inc. Common Stock's earnings and revenue for the latest quarter Q3 2025?
For Q3 2025, Kalaris Therapeutics, Inc. Common Stock reported EPS of -$0.64, beating estimates by 3.89%, and revenue of $0.00, 0% as expectations.
How did the market react to Kalaris Therapeutics, Inc. Common Stock's Q3 2025 earnings?
The stock price moved down -2.17%, changed from $5.07 before the earnings release to $4.96 the day after.
When is Kalaris Therapeutics, Inc. Common Stock expected to report next?
The next earning report is scheduled for 05 mar 2026.
What are the forecasts for Kalaris Therapeutics, Inc. Common Stock's next earnings report?
Based on 8
analistas, Kalaris Therapeutics, Inc. Common Stock is expected to report EPS of -$0.54 and revenue of -- for Q4 2025.
Which companies are reporting earnings today?
Cheque FXEmpire's Earnings Calendar for today's list of reporting companies.
Anuncio